Biohaven Ltd. (NYSE:BHVN) Given Average Rating of “Buy” by Analysts

Biohaven Ltd. (NYSE:BHVNGet Free Report) has been given an average rating of “Buy” by the sixteen analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eleven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $48.8462.

BHVN has been the topic of a number of recent analyst reports. UBS Group lowered their target price on Biohaven from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price (down from $54.00) on shares of Biohaven in a research note on Tuesday, August 12th. Bank of America lowered their target price on Biohaven from $50.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Leerink Partners lowered their target price on Biohaven from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th. Finally, Robert W. Baird lowered their target price on Biohaven from $57.00 to $52.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th.

View Our Latest Research Report on Biohaven

Institutional Investors Weigh In On Biohaven

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BHVN. Norges Bank bought a new stake in Biohaven in the 2nd quarter valued at about $12,735,000. Millennium Management LLC raised its stake in Biohaven by 1,172.9% in the 1st quarter. Millennium Management LLC now owns 901,258 shares of the company’s stock valued at $21,666,000 after acquiring an additional 830,457 shares during the period. Bellevue Group AG raised its stake in Biohaven by 37.3% in the 2nd quarter. Bellevue Group AG now owns 2,802,853 shares of the company’s stock valued at $39,548,000 after acquiring an additional 762,000 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Biohaven in the 2nd quarter valued at about $9,289,000. Finally, T. Rowe Price Investment Management Inc. bought a new stake in Biohaven in the 1st quarter valued at about $15,481,000. 88.78% of the stock is currently owned by institutional investors.

Biohaven Stock Performance

NYSE BHVN opened at $15.84 on Friday. Biohaven has a 1 year low of $12.79 and a 1 year high of $55.70. The company has a debt-to-equity ratio of 1.91, a current ratio of 3.82 and a quick ratio of 3.82. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -2.07 and a beta of 1.03. The company has a fifty day moving average price of $14.81 and a 200-day moving average price of $16.83.

Biohaven (NYSE:BHVNGet Free Report) last released its earnings results on Monday, August 11th. The company reported ($1.94) EPS for the quarter, hitting analysts’ consensus estimates of ($1.94). As a group, equities research analysts predict that Biohaven will post -8.9 EPS for the current fiscal year.

Biohaven Company Profile

(Get Free Report)

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

Read More

Analyst Recommendations for Biohaven (NYSE:BHVN)

Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.